The Infection Management Coalition (IMC) is a group of charities, professional societies, industry bodies and life science companies that have come together to advocate for a holistic approach to infection management to better protect our citizens, healthcare system and economy.
Our aim is to improve infection prevention, diagnosis and treatment, alongside comprehensive support for people affected by infection. Through our wide-ranging membership, we have access to expertise and information that can support the implementation of a more comprehensive and coordinated approach to infection.
We firmly believe in our collaborative multi-stakeholder approach to break down siloes in the system and support the UK Government’s ambitions to tackle challenges in antimicrobial resistance, sepsis and pandemic preparedness.
The IMC hopes to support the development of cohesive policy and deliver immediate and long-term change for the better. This means working collectively to publish infection management plans that include plans for AMR; resourcing all areas equally; creating a task force of stakeholders with equal voices; implementing an infection registry with patient level data and real-time tracking; ensuring valued consideration of the antimicrobial and diagnostics pipeline and delivering systems integration of infection management.
We have outlined our call to action within our White Paper (see below) alongside our supporting recommendations as a first step to achieve our collective aim of delivering transformational change that aligns to government policy and will benefit the NHS in delivery of effective patient treatment.
From our founding in 2021 and beyond, we have been and are continuing to focus on driving forward our recommendations and enabling policy change. Further detail on our work can be found below.
Globally, there are 4.95 million deaths per year associated with AMR1 and no new classes of antibiotics have been discovered since the 1980s.2 The time to act is now.
Secretariat provided by Hanover Communications
For more information, please contact imc@hanovercomms.com
IMC Parliamentary Event - July 2022
King’s Fund Annual Conference 2023 – November 2023
Infection Prevention and Control Conference (IPC) 2023 – April 2023
Lee Durnall (Menarini), Doris- Ann Williams MBE (former BIVDA), and Jonathan Pearce (Antibiotic Research UK) speaking at the IPC Conference 2023 to 127 attendees about the IMC.
If you would like to find out more about our work, or would be interested in joining the coalition, please contact Hanover Communications (IMC Secretariat): imc@hanovercomms.com
We launched our Whitepaper in February 2022, the first of its kind to outline detailed recommendations for holistic infection management. It sets out a bold vision for improved surveillance, prevention, screening, diagnosis, management and reporting of infection, paired with comprehensive support for people affected by infection and their families.
The IMC has identified four priority recommendations on the basis of their urgency, feasibility and impact.
This includes:
This includes:
This includes:
This includes:
Date of prep: August 2024
NP-NP-UK-0012 (content)
NP-NP-UK-0013 (link)
Compliance review of this website has been undertaken by A. Menarini Farmaceutica Internazionale SRL and bioMérieux UK Ltd.